Some unresolved issues with botulinum toxin

Issues concerning botulinum toxin still need resolution in the laboratory and clinic. Assay nomenclature is unsatisfactory and attempts to establish common units and/or equivalents are misguided and dangerous. Optimum toxin concentrations for most indications are unknown. Loss of response is too rea...

Full description

Saved in:
Bibliographic Details
Published inJournal of neurology Vol. 248 Suppl 1; no. 1; pp. 11 - I13
Main Author Guyer, B M
Format Journal Article
LanguageEnglish
Published Germany Springer Nature B.V 01.04.2001
Subjects
Animals
Anti-Dyskinesia Agents - immunology
Anti-Dyskinesia Agents - pharmacokinetics
Anti-Dyskinesia Agents - therapeutic use
Antibodies
Botulinum toxin
Botulinum Toxins - immunology
Botulinum Toxins - pharmacokinetics
Botulinum Toxins - therapeutic use
Dystonia
Humans
Lethal Dose 50
Membrane Proteins - metabolism
Nerve Tissue Proteins - metabolism
Neurology
Patients
Synaptosomal-Associated Protein 25
United Kingdom > UK
Online AccessGet full text

Cover

More Information
Summary:Issues concerning botulinum toxin still need resolution in the laboratory and clinic. Assay nomenclature is unsatisfactory and attempts to establish common units and/or equivalents are misguided and dangerous. Optimum toxin concentrations for most indications are unknown. Loss of response is too readily ascribed to antibody formation. New therapeutic indications for toxin raise the possibility of additional mechanisms of action.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0340-5354
1432-1459
DOI:10.1007/pl00007811